Soreq started her scientific career in the Weizmann Institute, where she served as Senior Scientist and then Associate Professor (1979-1986).

Soreq combines advanced sequencing technologies with computational neuroscience and transgenic engineering tools to investigate miR and tRF functions in the healthy and diseased brain and body, with a focus on acetylcholine (ACh)-related processes.

Her studies found primate-specific "CholinomiR" silencers of multiple genes that compete with each other on suppressing their targets and discovered cholinergic brain-to-body regulation of anxiety and inflammation.

[3] In human volunteers, Soreq found cholinergic-associated pulse increases under fear of terror;[4] and identified massive CholinomiRs decline in Alzheimer’s brains,[5] which accompanies changes in long non-coding RNAs and points at Statins intervention with the onset of Parkinson’s disease[6] and modifications in pseudogenes expression.

[10] Soreq has found CholinomiR differences between brains of men and women with schizophrenia and bipolar disorder,[11][12] and CholinomiRs decline accompanied by CholinotRF increases in blood cells from stroke patients;[13] together, her work leads to precision medicine-driven prevention and/or intervention with diseases involving impaired ACh signaling.